Adam Lerner, MD

Professor, Medicine

(617) 638-7504
650 Albany St Evans Biomed Research Ctr

Biography

Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.

Other Positions

  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Division of Graduate Medical Sciences
  • Professor, Pathology & Laboratory Medicine, Boston University School of Medicine
  • Active Staff Privileges, Hematology & Medical Oncology, Medicine, Boston Medical Center

Education

  • Yale University School of Medicine, MD
  • Amherst College, AB

Publications

  • Published on 9/1/2017

    de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80. PMID: 28867658.

    Read at: PubMed
  • Published on 8/30/2017

    Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2017 Aug 30; 1-8. PMID: 28853310.

    Read at: PubMed
  • Published on 8/10/2016

    Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):637-643. PMID: 27637428.

    Read at: PubMed
  • Published on 6/13/2016

    Xu C, Wyman AR, Alaamery MA, Argueta SA, Ivey FD, Meyers JA, Lerner A, Burdo TH, Connolly T, Hoffman CS, Chiles TC. Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol. 2016 Sep; 38:223-32. PMID: 27302770.

    Read at: PubMed
  • Published on 10/13/2015

    Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol. 2015; 6:230. PMID: 26528184.

    Read at: PubMed
  • Published on 5/20/2015

    Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015; 56(10):2847-54. PMID: 25791237.

    Read at: PubMed
  • Published on 1/1/2015

    Tan Y, Watkins AA, Freeman BB, Meyers JA, Rifkin IR, Lerner A. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol. 2015 Jan 1; 194(1):101-12. PMID: 25416804.

    Read at: PubMed
  • Published on 11/17/2014

    Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar; 168(6):811-9. PMID: 25404094.

    Read at: PubMed
  • Published on 9/8/2014

    Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014; 2:16. PMID: 25279222.

    Read at: PubMed
  • Published on 6/27/2014

    Tapan U, Pestana JB, Lee JC, Lerner A. Epstein-Barr virus-associated diffuse large B-cell lymphoma arising in atrial myxoma: a proposal for a modified therapeutic approach. Leuk Lymphoma. 2015 Feb; 56(2):505-7. PMID: 24794809.

    Read at: PubMed

View 38 more publications: View full profile at BUMC

View all profiles